Truist reiterates Buy on Boston Scientific stock amid 2027 outlook
Covered in this story
What has happened since
- Boston Scientific is up 3.0% since this was published, 13 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Truist Securities’s $51 target on $BSX is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
Truist Securities’s track record →Tracked from this story
RBC Capital Markets’s $52 target on $BSX is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
RBC Capital Markets’s track record →Tracked from this story
Canaccord Genuity’s $48 target on $BSX is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
Canaccord Genuity’s track record →Tracked from this story
Mizuho’s $50 target on $BSX is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
Mizuho’s track record →Analyst targets on Boston Scientific
- Bernstein: at $42.4 · target $54 by Oct 2027 · Outperform via Investing.com
- TD Cowen: at $47.8 · target $56 by Sep 2027 · Buy via Investing.com
- Stifel: at $48.2 · target $60 by Aug 2027 · Buy via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $BSX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Boston Scientific →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.